Q1 2023 Earnings Estimate for Krystal Biotech, Inc. (NASDAQ:KRYS) Issued By William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Equities researchers at William Blair cut their Q1 2023 earnings estimates for Krystal Biotech in a report issued on Monday, February 27th. William Blair analyst R. Prasad now forecasts that the company will earn ($1.20) per share for the quarter, down from their previous estimate of ($1.12). The consensus estimate for Krystal Biotech’s current full-year earnings is ($4.84) per share. William Blair also issued estimates for Krystal Biotech’s Q2 2023 earnings at ($1.22) EPS, Q3 2023 earnings at ($1.24) EPS, Q4 2023 earnings at ($1.07) EPS, FY2023 earnings at ($4.73) EPS and FY2024 earnings at ($2.94) EPS.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last posted its quarterly earnings data on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.01.

Other analysts also recently issued reports about the company. Guggenheim restated a “buy” rating and issued a $101.00 price objective on shares of Krystal Biotech in a report on Tuesday. The Goldman Sachs Group upgraded Krystal Biotech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $79.00 to $124.00 in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $119.00 price target on shares of Krystal Biotech in a research report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $133.00 price target on shares of Krystal Biotech in a research report on Tuesday.

Krystal Biotech Stock Down 1.4 %

NASDAQ KRYS opened at $81.82 on Thursday. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -14.85 and a beta of 0.87. Krystal Biotech has a twelve month low of $47.67 and a twelve month high of $89.59. The stock has a fifty day simple moving average of $79.38 and a 200 day simple moving average of $75.17.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, Director Dino A. Rossi sold 40,000 shares of the company’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the sale, the director now owns 83,691 shares of the company’s stock, valued at $6,967,275.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Suma Krishnan sold 22,148 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $80.77, for a total transaction of $1,788,893.96. Following the transaction, the insider now owns 1,680,115 shares of the company’s stock, valued at approximately $135,702,888.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dino A. Rossi sold 40,000 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the transaction, the director now directly owns 83,691 shares in the company, valued at approximately $6,967,275.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,844 shares of company stock valued at $9,034,599. 17.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Natixis bought a new position in Krystal Biotech in the 4th quarter valued at about $317,000. Alliancebernstein L.P. lifted its position in Krystal Biotech by 2.4% in the 4th quarter. Alliancebernstein L.P. now owns 26,100 shares of the company’s stock valued at $2,068,000 after acquiring an additional 600 shares in the last quarter. Capital Impact Advisors LLC lifted its position in Krystal Biotech by 5.2% in the 4th quarter. Capital Impact Advisors LLC now owns 5,419 shares of the company’s stock valued at $429,000 after acquiring an additional 269 shares in the last quarter. Silverarc Capital Management LLC lifted its position in Krystal Biotech by 3.3% in the 4th quarter. Silverarc Capital Management LLC now owns 58,535 shares of the company’s stock valued at $4,637,000 after acquiring an additional 1,890 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Krystal Biotech by 2.2% in the 4th quarter. Legal & General Group Plc now owns 7,120 shares of the company’s stock valued at $564,000 after buying an additional 155 shares during the last quarter. Institutional investors own 80.80% of the company’s stock.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases.